Not enough insurers signed on for the voluntary plan by the April deadline, so CMS instead announced it would extend the Bridge program to 18 months, with a new end date of December 2027
Three medications represent this progression: Semaglutide (single agonist, 15% average weight loss), Tirzepatide (dual agonist, 22.5% weight loss), and Retatrutide (triple agonist, 28.7% weight loss)
4 This was mostly driven by small-vessel occlusion prevention
Research protocols commonly include: Daily zinc supplementation Daily vitamin C supplementation alongside GHK-Cu-containing formulations
For patients and prescribers considering the use of glutathione 500 mg rectal suppositories, it is important to understand that while this formulation provides a targeted and efficient delivery of the active ingredient, it may not be suitable for all patients
Cardiovascular Health, Sleep Apnea, and More Retatrutide is also being evaluated in the TRIUMP Trial Program for potential benefits in cardiovascular health, obstructive sleep apnea, fatty liver disease, chronic kidney disease, and even pain associated with osteoarthritis